• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Gritstone bio Inc. (Amendment)

    2/14/24 4:26:22 PM ET
    $GRTS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $GRTS alert in real time by email
    SC 13G/A 1 tm245846d14_sc13ga.htm SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 7)

     

    Gritstone bio, Inc.

    (Name of Issuer)

     

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

     

    39868T105

     

    (CUSIP Number)

     

    December 31, 2023 

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    xRule 13d-1(b)

     

    ¨Rule 13d-1(c)

     

    ¨Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No. 39868T105

    1

    Name of Reporting Person

     

    Redmile Group, LLC

    2

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (A) ¨

     

    (B) ¨

    3 SEC Use Only
    4

    Citizenship or Place of Organization

     

    Delaware

    number of
    shares
    beneficially
    owned by
    each
    reporting
    person with
     

    5

    Sole Voting Power

     

    0

    6

    Shared Voting Power

     

    10,135,388 (1)

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    10,135,388 (1)

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    10,135,388 (1)

    10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
    11

    Percent of Class Represented by Amount in Row (9)

     

    9.9%(2)

    12

    Type of Reporting Person (See Instructions)

     

    IA, OO

     

     

    (1) Redmile Group, LLC’s beneficial ownership of the Issuer’s common stock (“Common Stock”) is comprised of 5,872,605 shares of Common Stock owned by certain private investment vehicles and/or sub-advised accounts managed by Redmile Group, LLC (collectively, the “Redmile Funds”), which shares of Common Stock may be deemed beneficially owned by Redmile Group, LLC as investment manager of the Redmile Funds. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any. Subject to the Beneficial Ownership Blocker (as defined below), Redmile Group, LLC may also be deemed to beneficially own 20,489,256 shares of Common Stock issuable upon exercise of certain Pre-Funded Warrants to Purchase Common Stock (the “Warrants”). Pursuant to the terms of the Warrants, a holder of a Warrant does not have the right to exercise any portion of the Warrant held by such holder, and any such exercise shall be void ab initio, to the extent (but only to the extent) that after giving effect to such issuance after exercise, the holder (together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates), would beneficially own in excess of 9.99% (the “Beneficial Ownership Limitation”) of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issued upon exercise of the Warrant (the “Beneficial Ownership Blocker”). The Beneficial Ownership Limitation may be changed at a holder’s election upon 61 days’ notice to the Issuer. The 10,135,388 shares of Common Stock reported as beneficially owned by Redmile Group, LLC in this Schedule 13G represents 9.99% of the outstanding shares of Common Stock (calculated in accordance with footnote (2) below).

    (2) Percentage based on the sum of (i) 95,342,055 shares of Common Stock outstanding as of November 6, 2023 as reported by the Issuer in its quarterly report on Form 10-Q for the quarterly period ended September 30, 2023 filed with the SEC on November 8, 2023 (the “Form 10-Q”); plus (ii) 4,262,783 shares of Common Stock issuable upon exercise of certain of the Warrants, which, due to the Beneficial Ownership Limitation, is the maximum number of shares that could be issued upon exercise of the Warrants; plus (iii) 1,850,500 shares of Common Stock issued to the Redmile Funds upon exercise of certain additional Warrants during the period after November 6, 2023 to December 31, 2023.

     

     

     

     

    CUSIP No. 39868T105

    1

    Name of Reporting Person

     

    Jeremy C. Green

    2

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (A) ¨

     

    (B) ¨

    3

    SEC Use Only

     

     

    4

    Citizenship or Place of Organization

     

    United Kingdom

    number of
    shares
    beneficially
    owned by
    each
    reporting
    person with
     

    5

    Sole Voting Power

     

    0

    6

    Shared Voting Power

     

    10,135,388 (3)

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    10,135,388 (3)

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    10,135,388 (3)

    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

    11

    Percent of Class Represented by Amount in Row (9)

     

    9.9%(4)

    12

    Type of Reporting Person (See Instructions)

     

    IN, HC

     

     

    (3) Jeremy C. Green’s beneficial ownership of Common Stock is comprised of 5,872,605 shares of Common Stock owned by certain Redmile Funds, which shares of Common Stock may be deemed beneficially owned by Redmile Group, LLC as investment manager of the Redmile Funds. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any. Subject to the Beneficial Ownership Blocker, Mr. Green may also be deemed to beneficially own 20,489,256 shares of Common Stock issuable upon exercise of the Warrants. Pursuant to the terms of the Warrants, the Issuer may not effect any exercise of any Warrant, and a holder of a Warrant does not have the right to exercise any portion of the Warrant held by such holder, to the extent that the Beneficial Ownership Blocker applies. The 10,135,388 shares of Common Stock reported as beneficially owned by Redmile Group, LLC in this Schedule 13G represents 9.99% of the outstanding shares of Common Stock (calculated in accordance with footnote (4) below).

    (4) Percentage based on the sum of (i) 95,342,055 shares of Common Stock outstanding as of November 6, 2023 as reported by the Issuer in the Form 10-Q; plus (ii) 4,262,783 shares of Common Stock issuable upon exercise of certain of the Warrants, which, due to the Beneficial Ownership Limitation, is the maximum number of shares that could be issued upon exercise of the Warrants; plus (iii) 1,850,500 shares of Common Stock issued to the Redmile Funds upon exercise of certain additional Warrants during the period after November 6, 2023 to December 31, 2023.

     

     

     

     

    Item 1.

     

    (a)Name of Issuer

     

    Gritstone bio, Inc.

     

    (b)Address of Issuer’s Principal Executive Offices

     

    5959 Horton Street, Suite 300

    Emeryville, California 94608

     

    Item 2.

     

    (a)Name of Each Person Filing (each, a “Reporting Person”)

     

    Redmile Group, LLC
    Jeremy C. Green

     

    (b)Address of Principal Business office or, if None, Residence

     

    Redmile Group, LLC
    One Letterman Drive
    Building D, Suite D3-300
    The Presidio of San Francisco
    San Francisco, California 94129

     

    Jeremy C. Green
    c/o Redmile Group, LLC (NY Office)
    45 W. 27th Street, Floor 11
    New York, NY 10001

     

    (c)Citizenship

     

    Redmile Group, LLC: Delaware
    Jeremy C. Green: United Kingdom

     

    (d)Title of Class of Securities

     

    Common Stock, $0.0001 par value per share

     

    (e)CUSIP Number

     

    39868T105

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

     

    (b)¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

     

    (c)¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

     

    (d)¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
         

     

     

     

    (e)x An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

     

    (f)¨ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

     

    (g)x A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

     

    (h)¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

    (i)¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

    (j)¨ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

     

    (k)¨ Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: _______

     

    Item 4.Ownership.

     

    (a)Amount beneficially owned:

     

    Redmile Group, LLC – 10,135,388*
    Jeremy C. Green – 10,135,388*
     

    (b)Percent of class:

     

    Redmile Group, LLC – 9.9%**
    Jeremy C. Green – 9.9%**

     

    (c)Number of shares as to which Redmile Group, LLC has:

     

    (i)Sole power to vote or to direct the vote: 0
    (ii)Shared power to vote or to direct the vote: 10,135,388*
    (iii)Sole power to dispose or to direct the disposition of: 0
    (iv)Shared power to dispose or to direct the disposition of: 10,135,388*

     

    Number of shares as to which Jeremy C. Green has:

     

    (i)Sole power to vote or to direct the vote: 0
    (ii)Shared power to vote or to direct the vote: 10,135,388*
    (iii)Sole power to dispose or to direct the disposition of: 0
    (iv)Shared power to dispose or to direct the disposition of: 10,135,388*

     

    *Redmile Group, LLC’s and Jeremy C. Green’s beneficial ownership of the Issuer’s Common Stock is comprised of 5,872,605 shares of Common Stock owned by the Redmile Funds, which shares of Common Stock may be deemed beneficially owned by Redmile Group, LLC as investment manager of the Redmile Funds. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any. Subject to the Beneficial Ownership Blocker, Redmile Group, LLC and Mr. Green may also be deemed to beneficially own 20,489,256 shares of Common Stock issuable upon exercise of the Warrants. Pursuant to the terms of the Warrants, the Issuer may not effect any exercise of any Warrant, and a holder of a Warrant does not have the right to exercise any portion of the Warrant held by such holder, if the Beneficial Ownership Blocker applies. The 10,135,388 shares of Common Stock reported as beneficially owned by the Reporting Persons in this Schedule 13G represent 9.99% of the outstanding shares of Common Stock

     

    **Percentage based on the sum of (i) 95,342,055 shares of Common Stock outstanding as of November 6, 2023 as reported by the Issuer in the Form 10-Q; plus (ii) 4,262,783 shares of Common Stock issuable upon exercise of certain of the Warrants, which, due to the Beneficial Ownership Limitation, is the maximum number of shares that could be issued upon exercise of the Warrants; plus (iii) 1,850,500 shares of Common Stock issued to the Redmile Funds upon exercise of certain additional Warrants during the period after November 6, 2023 to December 31, 2023.

     

     

     

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ¨

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    N/A.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

     

    See the response to Item 4.

     

    Item 8.Identification and Classification of Members of the Group.

     

    N/A.

     

    Item 9.Notice of Dissolution of Group.

     

    N/A.

     

    Item 10.Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

    SIGNATURE

     

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 14, 2024

     

     

    Redmile Group, LLC

         
      By: /s/ Jeremy C. Green
       

    Name: Jeremy C. Green

    Title: Managing Member

     

        /s/ Jeremy C. Green
     

    Jeremy C. Green

     

     

     

    Get the next $GRTS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GRTS

    DatePrice TargetRatingAnalyst
    10/1/2024Mkt Outperform → Mkt Perform
    JMP Securities
    2/28/2024$4.00Mkt Outperform
    JMP Securities
    3/31/2023Outperform
    Evercore ISI
    3/28/2023$8.00Buy
    B. Riley Securities
    10/31/2022$6.00Overweight
    Piper Sandler
    8/22/2022$2.00Neutral → Sell
    Goldman
    12/15/2021$15.00Neutral
    Goldman
    10/15/2021$20.00Buy
    BTIG Research
    More analyst ratings

    $GRTS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Gritstone bio Takes Action to Preserve Value and Strengthen Capital Structure

      Voluntarily Files for Chapter 11 Restructuring Strategic Alternatives Process Continues with Interest from Parties Gritstone bio, Inc. (NASDAQ:GRTS) ("Gritstone" or the "Company"), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced it has filed a voluntary petition under chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware. Gritstone intends to use the court-administered restructuring process to preserve value and support its ongoing strategic alternatives process. The Company is in discussions with a party to act as a stalking horse bidder or plan sponsor and intends to

      10/10/24 5:50:00 AM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gritstone bio Announces Interim Phase 2 Data for GRANITE Individualized Neoantigen Targeting Immunotherapy in Frontline Metastatic Microsatellite Stable Colorectal Cancer

      --Encouraging progression-free survival data in overall population; continued follow-up needed to allow data to mature further, especially in low ctDNA subgroup where events accrue more slowly --21% relative risk reduction of progression or death with GRANITE vs. control in all treated population (HR=0.79 [95% CI, 0.42-1.50])-- -- 38% relative risk reduction of progression or death with GRANITE vs. control in low ctDNA subgroup (HR=0.62 [95% CI, 0.23-1.70]) -- -- Strength of neoantigen specific T cell responses in GRANITE patients appears to associate with progression-free survival -- GRANITE was generally well-tolerated with no treatment discontinuations due to adverse events– -- Overa

      9/30/24 4:05:00 PM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gritstone bio Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

      -- Preliminary randomized Phase 2 data suggest GRANITE (personalized neoantigen vaccine) could drive meaningful clinical benefit in front-line metastatic microsatellite-stable colorectal cancer (MSS-CRC); mature progression-free survival (PFS) data expected in the third quarter of 2024 -- -- Recent KOL event and patient advocacy engagements underscore the unmet need for new treatment options in metastatic colorectal cancer -- -- Presentations at AACR 2024 and ESCMID Global 2024 demonstrate the broad potential of Gritstone's oncology and infectious disease vaccines -- -- Cash, cash equivalents, marketable securities and restricted cash of $61.7 million as of June 30, 2024 -- EMERYVILLE, C

      8/13/24 4:05:00 PM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GRTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • PRESIDENT AND CEO Allen Andrew R gifted 650,000 shares, decreasing direct ownership by 25% to 985,360 units (SEC Form 4)

      4 - Gritstone bio, Inc. (0001656634) (Issuer)

      6/26/24 9:25:58 PM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Fisher Clare

      4 - Gritstone bio, Inc. (0001656634) (Issuer)

      6/20/24 6:23:33 PM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Agarwal Shefali

      4 - Gritstone bio, Inc. (0001656634) (Issuer)

      6/20/24 6:19:11 PM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GRTS
    SEC Filings

    See more
    • Gritstone bio Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities

      8-K - Gritstone bio, Inc. (0001656634) (Filer)

      10/16/24 4:06:00 PM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gritstone bio Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Regulation FD Disclosure

      8-K - Gritstone bio, Inc. (0001656634) (Filer)

      10/10/24 8:29:59 AM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 8-K filed by Gritstone bio Inc.

      8-K - Gritstone bio, Inc. (0001656634) (Filer)

      9/30/24 8:05:58 PM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GRTS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Gritstone bio Inc.

      SC 13G/A - Gritstone bio, Inc. (0001656634) (Subject)

      11/6/24 5:34:44 PM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Gritstone bio Inc.

      SC 13G - Gritstone bio, Inc. (0001656634) (Subject)

      10/7/24 5:01:07 PM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Gritstone bio Inc.

      SC 13G/A - Gritstone bio, Inc. (0001656634) (Subject)

      7/8/24 4:32:39 PM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GRTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Gritstone bio downgraded by JMP Securities

      JMP Securities downgraded Gritstone bio from Mkt Outperform to Mkt Perform

      10/1/24 7:33:47 AM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JMP Securities initiated coverage on Gritstone bio with a new price target

      JMP Securities initiated coverage of Gritstone bio with a rating of Mkt Outperform and set a new price target of $4.00

      2/28/24 6:17:40 AM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Evercore ISI initiated coverage on Gritstone bio

      Evercore ISI initiated coverage of Gritstone bio with a rating of Outperform

      3/31/23 8:59:35 AM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GRTS
    Financials

    Live finance-specific insights

    See more
    • Gritstone bio to Report First Quarter 2024 Financial Results and Provide Corporate Updates on May 9, 2024

      -- Conference call and webcast to begin at 4:30pm ET -- EMERYVILLE, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced it will report financial results for the first quarter 2024 and provide corporate updates after market close on Thursday, May 9, 2024. The announcement will be followed by a conference call and audio webcast, which will begin at 4:30pm ET. To access by phone, dial: 1-877-407-4018Conference ID: 13746126To access by webcast, visit: https://viavid.webcasts.com/starthere.jsp?ei=1667088&tp_key=d0e680f7aa While not required, it is recommended yo

      5/2/24 4:05:00 PM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gritstone bio Reports First Quarter 2023 Financial Results and Provides Corporate Updates

      -- Robust enrollment in Phase 2 portion of randomized Phase 2/3 study of GRANITE (personalized vaccine in first-line metastatic microsatellite-stable colorectal cancer [MSS-CRC]) to date; 71 of 80 patients (initial target) enrolled as of May 10, 2023 -- -- Gritstone prioritizing GRANITE; expanding Phase 2 from 80 to 100 patients, enrollment completion expected in 3Q2023, preliminary data on approximately 50 patients expected in 1Q2024 -- -- Cash, cash equivalents, marketable securities, and restricted cash of $153.2 million as of March 31, 2023 -- -- Gritstone to host conference call today at 4:30pm ET -- EMERYVILLE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ

      5/11/23 4:05:00 PM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gritstone bio to Report First Quarter 2023 Financial Results and Provide Corporate Update on May 11, 2023

      EMERYVILLE, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced it will report its first quarter 2023 financial results and provide a corporate update following market close on Thursday, May 11, 2023. The announcement will be followed by a conference call and audio webcast, which will begin at 4:30pm ET. Live Conference Call & WebcastToll Free: 1-888-999-6281International: 1-848-280-6550Conference ID: 1754341Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1612896&tp_key=c6c637ac24 While not required, it is recommended you join five minutes prior to the

      5/3/23 7:00:00 AM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GRTS
    Leadership Updates

    Live Leadership Updates

    See more
    • Gritstone bio Announces Appointment of Stephen Webster to its Board of Directors

      EMERYVILLE, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced the appointment of Stephen Webster to its Board of Directors. A veteran finance executive in the biotechnology industry, Mr. Webster has served as an executive for several renowned companies and held key roles in raising capital, business development transactions and operations for over 30 years. The company also announced that Steve Krognes will not stand for re-election at the 2024 Annual Meeting. "We are excited to welcome Stephen Webster to our Board of Directors at this important and excit

      4/29/24 7:00:00 AM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gritstone bio Presents Improvements to EDGE™ Platform at AACR 2024

      -- State-of-the-art neoantigen prediction platform (EDGE™) now predicts HLA Class I presentation of epitopes with >80% accuracy -- -- Newly developed EDGE-II model achieves superior predictive performance of HLA Class II presentation and CD4+ immunogenicity over publicly available models -- -- Combined with Gritstone's vaccine vectors, EDGE has demonstrated best-in-class potential in identifying neoantigens capable of eliciting T cell immune responses for robust and durable immunity -- EMERYVILLE, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today presented an upd

      4/8/24 7:00:00 AM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Predictive Oncology Appoints Leading Biopharma Executive Matthew J. Hawryluk Ph.D. to the Board of Directors

      EAGAN, Minn., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI) is pleased to announce the appointment of Matthew J. Hawryluk, Ph.D., (www.predictive-oncology.com) to its Board of Directors to help support the company's strategic initiatives and commercialization efforts. Dr. Hawryluk currently serves as Executive Vice President and Chief Business Officer of Gritstone bio, Inc (NASDAQ:GRTS). Recognized by Pharmaceutical Executive magazine as a leading business executive in the pharma and biotech industries, Dr. Hawryluk has played key roles in bridging the gap between scientific discovery and the commercial application of scientific breakthroughs. As a named invento

      12/5/22 8:30:00 AM ET
      $GRTS
      $POAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Industrial Specialties